Macrophage activation syndrome with acute hepatitis E during tocilizumab treatment for rheumatoid arthritis.

Marie Leroy , Guillaume Coiffier (1) , Charlotte Pronier , Louise Triquet , Aleth Perdriger (2) , Pascal Guggenbuhl (2, 3)

1 Service de néphrologie [Rennes]
2 Service de rhumatologie [Rennes] = Rheumatology [Rennes]
3 Foie, métabolismes et cancer

Tocilizumab is a humanized antibody against the membrane and soluble receptors for interleukin-6. Tocilizumab is among the disease-modifying antirheumatic drugs (DMARDs) used to treat moderate-to-severe active rheumatoid arthritis (RA) refractory to conventional DMARDs. We report a case of macrophage activation syndrome that complicated acute hepatitis E and started within 24hours after the fourth tocilizumab infusion in a patient with RA.

Mots clés: Acute hepatitis E; Macrophage activation syndrome; Rheumatoid arthritis; Tocilizumab

Domaines: Sciences du Vivant [q-bio]

Marie Leroy, Guillaume Coiffier, Charlotte Pronier, Louise Triquet, Aleth Perdriger, et al.. Macrophage activation syndrome with acute hepatitis E during tocilizumab treatment for rheumatoid arthritis.. Joint Bone Spine, 2015, 82 (4), pp.278-279. ⟨10.1016/j.jbspin.2015.01.018⟩. ⟨hal-01134354⟩